Cardiol Therapeutics Inc.
CRDL.TO
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 14.47M | 14.70M | 14.54M | 14.86M | 18.56M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.72M | 25.68M | 24.57M | 25.95M | 28.93M |
| Operating Income | -25.72M | -25.68M | -24.57M | -25.95M | -28.93M |
| Income Before Tax | -24.47M | -26.23M | -24.22M | -24.89M | -26.99M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -24.47 | -26.23 | -24.22 | -24.89 | -26.99 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -24.47M | -26.23M | -24.22M | -24.89M | -26.99M |
| EBIT | -25.72M | -25.68M | -24.57M | -25.95M | -28.93M |
| EBITDA | -25.69M | -25.64M | -24.52M | -25.88M | -28.72M |
| EPS Basic | -0.25 | -0.28 | -0.28 | -0.30 | -0.35 |
| Normalized Basic EPS | -0.15 | -0.18 | -0.18 | -0.19 | -0.22 |
| EPS Diluted | -0.25 | -0.28 | -0.28 | -0.30 | -0.35 |
| Normalized Diluted EPS | -0.15 | -0.18 | -0.18 | -0.19 | -0.22 |
| Average Basic Shares Outstanding | 406.59M | 374.31M | 347.93M | 330.40M | 315.51M |
| Average Diluted Shares Outstanding | 406.59M | 374.31M | 347.93M | 330.40M | 315.51M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |